Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Proteome Sciences Plc LSE:PRM London Ordinary Share GB0003104196 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 3.60 0.00 16:29:45
Bid Price Offer Price High Price Low Price Open Price
3.20 4.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 5.13 0.12 0.02 180.0 11
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 3.60 GBX

Proteome Sciences (PRM) Latest News

More Proteome Sciences News
Proteome Sciences Investors    Proteome Sciences Takeover Rumours

Proteome Sciences (PRM) Discussions and Chat

Proteome Sciences Forums and Chat

Date Time Title Posts
28/6/202213:05Proteome Sciences leading Alzheimer's technology.91,346
25/6/202221:58Proteome, what next? (moderated)59,255
13/5/202019:36Only worth 3p on fundamentals....10
28/4/202007:22Proteome Sciences plc, A Three Horse Race for the Month of May.4,854
02/7/201917:54The useful PRM thread13

Add a New Thread

Proteome Sciences (PRM) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Proteome Sciences trades in real-time

Proteome Sciences (PRM) Top Chat Posts

DateSubject
28/6/2022
09:20
Proteome Sciences Daily Update: Proteome Sciences Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker PRM. The last closing price for Proteome Sciences was 3.60p.
Proteome Sciences Plc has a 4 week average price of 3.35p and a 12 week average price of 3.35p.
The 1 year high share price is 7.20p while the 1 year low share price is currently 3.31p.
There are currently 294,648,723 shares in issue and the average daily traded volume is 195,792 shares. The market capitalisation of Proteome Sciences Plc is £10,607,354.03.
26/6/2022
07:19
badger60: DC So, Pearce wouldn't even buy a round in the pub after he and Diggle have fleeced PRM shareholders out millions....that sounds about right. You have to be surprised that Goaty still owns over a million shares......I thought it would be a lot more.......and it probably is if you add your holding to it...... See you back on the OXB unfettered thread....;+) (I'm not wealthy enough to qualify for "Wealth Management"........nor are many PRM and OXB shareholders).
22/6/2022
13:33
tom barnaby: Thsi was the pointless secondary avatars first post. wasjobber - 20 May 2006 - 13:34:34 - 35378 of 61526 Proteome Sciences. AGM Statement. - PRM Shorters of this stock are going to get caught out big time!
22/6/2022
13:20
peverill: Numerous CEO'S,They paid Haigh £750k,for what,he couldn't do anything,Mariola coming up on 2 years,nothing worth shouting about,a share price of 3p.They owe a major shareholder over a million,they can't pay,its founder £10m.Yet still pay the largest part of earnings on over inflated wages just doesn't add up.
22/6/2022
10:51
wasjobber: The roll out of PRM licensed tech across the US & Europe
12/5/2022
12:23
dominiccummings: Share price holding up well in these difficult times. That's the one advantage of being a 'bombed out wreck' of a company..... can't go lower!
12/5/2022
07:08
wrighty41: Nice one PRM. Growing revenues over next 3yrs which will eventually reflect in a 10p+ share price imo W41
31/3/2022
11:29
monte1: A serious question to the floor; Revenue has increased slightly - hurrah - and adjusted admin costs have been fairly well controlled - yay - so as an apparent reward, employee share options have been granted (presumably to the bod) resulting in a share-based payment charge of 570k thereby reducing the ebitda to a level below last year. Great for those granted these options but when are long suffering shareholders going to get even the smallest share of this glacial ‘adjusted̵7; progress? There will be no divis in the foreseeable so a progression in EBITDA will surely be required to spark some appreciation in the share price and with options seemingly being granted willy-nilly on top of incredibly generous remuneration in relation to turnover this is getting kicked further down the road.
30/3/2022
08:20
monte1: Not quite £53 then? SIMPLY WALLST Hello Xxxxxx, you have 1 new important update for PRM Proteome Sciences PRM Share Price 7 Day 1 Year 0.04 -8.9% -24.4% Now 25% undervalued after recent price drop Over the last 90 days, the stock is down 31%. The fair value is estimated to be UK£0.048, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% per annum over the last 3 years. The company has become profitable over the last 3 years.
31/12/2021
12:30
stocktastic: Last seen ramping a £25/share OXB takeover story.... ... conveniently just before a placing (nice for a large holder to have buying and a supported share price just when a £50m stake is taken) And before the share price then lost 33% For other reasons,but who knows which orgs trade the volatility and take out stops etc Canaletto28 Dec '21 - 12:04 - 90832 of 90837 0 0 0 What about tuco1
12/8/2021
13:03
tom barnaby: Happy birthday. 14 years old today. Peter Snodgrass - 12 Aug'07 - 13:06 - 6869 of 53300 PRM – The AIM - updated brief for newcomers. As is well known, our CEO set up Fitness First to generate the funds necessary to finance his life’s ambition - which was and is to find a cure for the sort of disease that killed his young daughter. With the resulting £50m profit from that venture (recently augmented by a further £22m from another) he set up what has become PRM and also took a controlling stake in Intronn (from which Veri-Q was also derived). Backed by over £70m (and contrary to what the bashers claim) PRM has never had, nor will have, any financing problems whatsoever. Our brilliant CEO then had the foresight to put PRM ahead of the personalised medicine world by going down the proteomic route – but by 03 realised that to stay ahead of the growing competition, and prevent a hostile takeover, he needed the assistance and protection of a much bigger company. The Amersham/GE link up (first publicised in early October 03) and the invitation to PRM to join it as part of the proposed new GE Healthcare Division was seized by our CEO as a wonderful opportunity to help him achieve his aim. My research has indicated that the decision to accept that GE invitation was taken – subject to the Amersham deal being approved – towards the end of Q3 03. It became based on the standard GE agreement terms for the future takeover of companies which had not yet become profitable. That agreement included a confidentiality clause and remained confidential when it became fully effective with GE in April 04. The terms included GE taking over most, if not all, of the commercialisation of PRM’s IP in GE’s name. That was all due to be announced in May 04 when PRM was expected to become profitable as a result of the Sensitizer (TMT) licence deal already arranged for the end of 03 but postponed until the formation of GE Healthcare was completed in April 04. Instead, due to the only recently fully resolved TMT patent “bombshellR21; issue, those arrangements had to be abandoned and the agreement has remained confidential ever since – although it has become obvious to anyone who later has done their research thoroughly from the spring of 2003 onwards. In fact, from Q4 03, PRM ceased to be a company whose prospects and share price could be assessed by normal criteria. With GE/Amersham in close collaboration with PRM on developing PRM’s IP and GE taking over practically all commercialisation if it (but allowing three non profitable research licences to be announced in PRM’s name when needed to help the share price) GE now only have to complete the TMT licence negotiations (thereby making PRM “profitable221;) for the takeover to be announced. For the last nearly four years, however, PRM has been bound by the confidentiality clause from revealing the agreement with GE. In consequence – and in spite of the fact that the arrangements with GE were clearly publicised on the BB from January 04 onwards – most investors have chosen to ignore the obvious and have assessed PRM as they would any other company which depended on revenues, forecast P/E ratios etc to judge its share price and the performance of the Board etc. But, in fact, it is only the potential value of its IP on which PRM’s share price should have been decided - all the usual criteria have been, and remain, irrelevant. Hence the enormous discrepancy that has built up between the share price and likely takeover value. Judging by the nonsense they post and the ridiculous share price, many investors still fail to realise that PRM is almost unique in that respect. The ONLY thing that really matters is the potential value of the patents resulting from PRM's brilliant research - and the use that GE Healthcare and PRM have made, and are making, of them. Unfortunately, the original agreement (which I think - and sincerely hope - may recently have been amended) was in the standard GE form for companies not yet profitable with the takeover price being x3 the average price of the three years preceding the offer. That was originally expected to result in a price way above £3. But now, over three years later during which time its value has increased enormously, it works out at only around 189p. It is for this reason (ie the low share price) that our CEO has repeatedly kept delaying completing the TMT (and other) licensing deal(s). PRM has never been equipped to negotiate licences with any big pharma, but I am hoping (and have reason to believe) that our CEO has reached agreement with GE for the BIG deal. Hopefully too, when that is announced, we should also get information on the other IP which GE have been helping exploit – including Intronn, Veri-Q, Alzheimer’s (with the patented vaccine from Mindset as well), Organ Transplant Rejection, the JV for the cancers, the HTS deals with 20 companies, and perhaps more Proteoshop etc.'[ Additional note 25 Aug - I have received indications that one, possibly two, HTS licensing deal(s) may be announced in the relatively near future. The implications for the share price, if that occurs, would be considerable.] Maybe, however, we shall just get only the takeover offer. But when? I have been so wrong in my earlier forecasts of timing that I am reluctant to suggest when that will be announced. But it seems logical to expect it when the first of the TMT licences (being negotiated by GE) is signed. Based on the original agreement, GE’s first low takeover offer CANNOT be below around 189p. Furthermore, I believe PRM will fight hard against any offer below £5. Yet the share price is 55p. That ridiculous price must, I believe, be being forced down by some ignorant big sellers. But with the TMT deals and takeover “in the bag” it does seem a most extraordinary situation. All above IMO/DYOR. Regards to all LTHs, Peter. Please also see my update post 7328 of 22 Aug 07.
Proteome Sciences share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
PRM
Proteome S..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220628 21:00:14